Device Trial Radar · NCT02701283
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,223
Actual
Start
Mar 2016
Primary completion
Apr 2021
Study completion Jun 2029
Sponsor
- Lead sponsor
- Medtronic CardiovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Mar 8, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR. The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.
Conditions
- Aortic Valve Stenosis
Interventions
Medtronic Transcatheter Aortic Valve Replacement SystemsDevice
Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
Surgical Aortic Valve Replacement (SAVR)Device
Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: All Cause Mortality or Disabling Stroke Rate at 24 Months, Randomized Controlled Trial Safety: All Cause Mortality or All Stroke Rate at 12 Months, Continued Access StudyTime frame: Randomized Controlled Trial - 24 months Continued Access Study - 12 months
Locations
87 sites in 7 countries. Site status is shown where the registry gives one.
Abrazo Arizona Heart Hospital
Phoenix, Arizona
Scripps Memorial Hospital La Jolla
La Jolla, California
University of Southern California University Hospital
Los Angeles, California
84 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.